Canadian Hemophilia Society
Help Stop the Bleeding
British Columbia Chapter
|Our Mission||Who we are||Clinic||Chapter Programs||Hemophilia News||Events||Acknowledgements||Forms||Pictures|
Surplus in the Trust Fund for the 1986-1990 Hepatitis C Settlement Agreement
Liberal Government's quarter-billion dollar broken promise that no one talks (or knows) about
The CHS, along with several other organizations, objects to the surplus being paid out to the federal government and strongly supports a Notice of Motion, which will be presented to the courts at a Joint Hearing in June, to enhance the benefit to claimants....
Kogenate FS Withdrawal
On August 15, Bayer Inc. withdrew nineteen lots of Kogenate FS distributed in Canada. These lots of Kogenate FS currently meet potency requirements but have been identified as being at risk of falling below potency before their expiry date.
Hepatitis C Class Action Settlement (1986-1990)
1. Factums by the Joint Commitee and the Federal Government IMPORTANT NOTICE: Joint Hearing will take place June 20-22, 2016
Nuwiq approved in Canada - Octapharma
Octapharma's new generation recombinant FVIII (Nuwiq) is now approved in Canada for treatment and prophylaxis of bleeding in patients of all ages suffering with hemophilia A (congenital factor VIII deficiency).
Pfizer's Solofuse reconstitution device now available in Canada
The first reconstitution device in the form of a syringe prefiled with diluent and recombinant factor VIII (Xyntha).
KidK, A Self Infusion Training Program - Bayer
Bayer HealthCare has created an educational tool for patients with hemophilia A. The program is designed to help healthcare professionals teach patients how to self-infuse. The kit includes a new tool called BayCuff which helps patients learn and practice how to safely self-infuse.
Step Up, Reach Out International Leadership Program for Youth (SURO) and AFFIRM - Bayer
Two flagship patient advocacy development programs, SURO & AFFIRM are international programs designed to provide hands-on leadership training for future patient orgaization leaders between 18-38 years old, who are interested in actively supporting their hemophilia communities.
Speaking Frankly - Bayer
A series of peer-written magazines in print and online which offers advice on some of early adulthood's difficult and controversial questions. It is an insightful tool for young adults with hemophilia which covers taboo topics such as sex, drugs and depression. Copies of past editions can be obtained through the BC Hemophilia Assessment Clinic.
If you are planning a trip or are travelling into clinic, there are two new resources available to you:
"Getting There" Travel, Accommodation and Transportation Resource Guide - a booklet that highlights potential discounts and savings for patients travelling into clinic.
- if you are planning a trip this booklet will outline what you should be considering regarding your bleeding disorder.
Introducing eHemophilia, an online learning opportunity designed by McMaster University to benefit your health care professional. This program is supported by a restricted grant from Bayer HealthCare.
Graphic Novels for Young People with Hemophilia- Bayer
K Living With It!... an exciting graphic novel series. Available to patients and their siblings accross Canada through your local clinic or chapter. Please vist the BC Hemophilia Assessment Clinic to obtain copies of past editions.
A Bright Future - DVD Series
Me and My Genes
A resource about being a carrier of hemophilia is now available. Me and My Genes is an interactive animated video that provides potential pre-teen and teenage carriers with relevant and age appropriate information about what it means to be a carrier of hemophilia A or B. It includes facts about inheritance of the hemophilia gene, carrier testing and the management of bleeding symptoms. The resource also includes interactive buttons for viewers to test their knowledge and access tips, myths and fun facts of interest for young carriers.
Is life without bleeds a possibility?
Health Canada approves Eloctate - Biogen
August 2014 - Biogen Idec Canada is pleased to announce that Health Canada has approved ELOCTATE Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein for the control and prevention of bleeding episodes and routine prophylaxis in adults and children aged 12 and older with hemophilia A.